We are analyzing https://link.springer.com/article/10.1007/s11523-016-0427-8.

Title:
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib? | Targeted Oncology
Description:
Targeted Oncology -
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Telecommunications
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, sorafenib, cas, google, scholar, pubmed, hepatocellular, carcinoma, clin, advanced, faivre, patients, oncol, privacy, cookies, sandrine, phase, iii, cancer, content, publish, search, oncology, gramont, raymond, access, trial, results, data, information, log, journal, research, hcc, armand, eric, sunitinib, versus, randomized, download, author, paris, springer, optional, analysis, personal, parties, policy, find, track,

Topics {✒️}

month download article/chapter combination anti-vegf therapy armand de gramont eric raymond declare pharmacokinetic/pharmacodynamic meta-analysis full article pdf privacy choices/manage cookies phase iii randomised phase iii failure portal hypertensive syndrome anti-viral effect article faivre placebo-controlled trial de gramont european economic area asia-pacific region liver dysfunction [abstract aliment pharmacol ther aragon-ching jb renal cell carcinoma ethics declarations funding advanced hepatocellular carcinoma conditions privacy policy cancer chemother pharmacol hepatocellular carcinoma [hcc] advanced hepatocellular cancer brivanib versus sorafenib linifanib versus sorafenib cumulative sorafenib dose sorafenib-induced hypertension accepting optional cookies sandrine faivre clin cancer res sunitinib versus sorafenib article log journal finder publish author correspondence books a exposure-toxicity relationship article cite check access instant access hepatocellular carcinoma limaye ar privacy policy personal data meta-analysis université paris 7 trial design optional cookies

Questions {❓}

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
         description:
         datePublished:2016-03-21T00:00:00Z
         dateModified:2016-03-21T00:00:00Z
         pageStart:565
         pageEnd:567
         sameAs:https://doi.org/10.1007/s11523-016-0427-8
         keywords:
            Sorafenib
            Sunitinib
            Overall Response Rate
            Sorafenib Treatment
            Adverse Event Management
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0427-8/MediaObjects/11523_2016_427_Fig1_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sandrine Faivre
               affiliation:
                     name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
                     address:
                        name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
                        type:PostalAddress
                     type:Organization
                     name:Hôpital Beaujon
                     address:
                        name:Medical Oncology, Hôpital Beaujon, Clichy, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Armand de Gramont
               affiliation:
                     name:Centre Hospitalier Universitaire Lausanne (CHUV)
                     address:
                        name:Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric Raymond
               affiliation:
                     name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
                     address:
                        name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
      description:
      datePublished:2016-03-21T00:00:00Z
      dateModified:2016-03-21T00:00:00Z
      pageStart:565
      pageEnd:567
      sameAs:https://doi.org/10.1007/s11523-016-0427-8
      keywords:
         Sorafenib
         Sunitinib
         Overall Response Rate
         Sorafenib Treatment
         Adverse Event Management
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0427-8/MediaObjects/11523_2016_427_Fig1_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sandrine Faivre
            affiliation:
                  name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
                  address:
                     name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
                     type:PostalAddress
                  type:Organization
                  name:Hôpital Beaujon
                  address:
                     name:Medical Oncology, Hôpital Beaujon, Clichy, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Armand de Gramont
            affiliation:
                  name:Centre Hospitalier Universitaire Lausanne (CHUV)
                  address:
                     name:Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric Raymond
            affiliation:
                  name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
                  address:
                     name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:11
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
      address:
         name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
         type:PostalAddress
      name:Hôpital Beaujon
      address:
         name:Medical Oncology, Hôpital Beaujon, Clichy, France
         type:PostalAddress
      name:Centre Hospitalier Universitaire Lausanne (CHUV)
      address:
         name:Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), Lausanne, Switzerland
         type:PostalAddress
      name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
      address:
         name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sandrine Faivre
      affiliation:
            name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
            address:
               name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
               type:PostalAddress
            type:Organization
            name:Hôpital Beaujon
            address:
               name:Medical Oncology, Hôpital Beaujon, Clichy, France
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Armand de Gramont
      affiliation:
            name:Centre Hospitalier Universitaire Lausanne (CHUV)
            address:
               name:Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Eric Raymond
      affiliation:
            name:Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS)
            address:
               name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
      name:Medical Oncology, Hôpital Beaujon, Clichy, France
      name:Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), Lausanne, Switzerland
      name:Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(64)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.18s.

LINK . SPRINGER . COM {}